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 In light of the recent success of immune checkpoint blockade in cancer treatments, 
new inhibitory molecules and pathways have been increasingly considered as targets for 
cancer immunotherapy. The adenosine A2A receptor has long been regarded as an important 
checkpoint target given its role in anti-inflammation and immune suppression. At the same 
time, the tumor environment has also been found to contain high levels of adenosine as a 
consequence of hypoxia, inflammation, and cell death. The result of this phenomenon is 
often a suppression of activated lymphocytes, natural kills cells, and antigen-presenting 
cells, along with the up-regulation of inhibitory T cells. 
 
 To combat the evasion by the tumor cells and avoid further exploitation of the 
adenosine pathway, numerous strategies have been proposed including the use of 
monoclonal antibodies to block CD73, an adenosine-generating ecto-5’-nucleotidase 
expressed on the surface of tumor cells. Alternatively, potent and selective small-molecule 
antagonists to the A2A receptor can also prevent activation of the receptor, hence the 
downstream signaling pathways that lead to immune suppression. However, most 
antagonists developed previously have drawbacks such as short pharmacokinetic half-lives 
and potential systemic toxicity due to the expression of A2AR in the brain and the heart.  
 
 In my thesis research, we conjugated a potent, selective A2A receptor antagonist, 
ZM-241,385, to the fragment crystallizable (Fc) region of immunoglobulins to overcome 
these pharmacologic barriers to A2A receptor inhibition. Our synthetic approach utilizes the 
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advantage of expressed protein ligation to site-specifically and reproducibly link the two 
moieties, ZM-241,385 and Fc, together. The resulting product, Fc-ZM, retained functional 
interactions with the A2A receptor and Fc receptors as confirmed by in vitro binding and 
functional assays. More importantly, Fc-ZM was shown to have superior pharmacologic 
properties in blocking the adenosine checkpoint pathway in mice, thereby enhancing the 
immune response in vivo. Overall, my thesis research provides a reproducible method of 
synthesizing Fc-conjugated small molecules, and demonstrate the ability of Fc conjugation 
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 Technological advances in the understanding, production, and use of biologics have 
greatly accelerated the growth of cancer immunotherapy in the past two decades. Today, 
cancer immunotherapy comes in various forms including antibody-based, cell-based, 
virus-based, and non-targeted methods (Fig. 1). These methods help boost our immune 
system by doing one of two things: stimulate the immune cells to work harder and smarter, 
or provide the system with critical components to speed up and strengthen the immune 
response. This is because our immune system sometimes does not recognize cancer cells 
as foreign or, in cases where recognition happens, the response might not be robust enough 
to destroy the cancer cells. At the same time, cancer cells themselves can also release 
substances to dampen or even shut down the immune response. As the cancer cells evolve 
their immunogenicity in order to survive the attacks from the immune system, the result is 
often the emergence of immune-resistant tumors.  
 
 This dynamic process involving immunosurveillance and tumor progression is 
known as immunoediting (Fig. 2), and occurs in three steps: elimination, equilibrium, and 
escape[1]. The first phase, elimination, refers to the innate and adaptive immune responses 
to the tumor. Natural killer (NK) cells, lymphocytes, macrophages and other immune cells 
work together to destroy cancer cells by cytotoxic mechanisms such as perforin, TNF-
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related apoptosis-inducing ligands, and reactive oxygen species[2]. Next, in the 
equilibrium phase, cancer cells that have survived the elimination enter into an equilibrium 
with the host immune system, wherein lymphocytes and cytokines such as IFN-γ continue 
to exert pressure that is sufficient to contain, but not fully extinguish, the tumor. During 
this relatively long period of Darwinian selection, new variants of the original tumor with 
reduced or non-immunogenic phenotypes arise and are selected for proliferation[2]. Lastly, 
during the escape phase, the host’s immune defense system is effectively breached, with 
the cancer cells selected in the equilibrium phase expanding without any detection and 
elimination. Although most cancers observed clinically have progressed through the 
escape phase, it remains critically important to understand the underlying mechanisms that 
give rise to immune tolerance for the design and the development of better, more effective, 
immunotherapies. 
 
 One of the first examples of immunotherapy for cancer is the use of Bacillus 
Calmette-Guérin (BCG) for treating superficial forms of bladder cancer. In fact, the BCG 
vaccine has been used as standard of care for patients with non-muscle-invasive bladder 
cancer (NMIBC) since 1977, nearly 40 years ago[3]. The antitumor effect of BCG is 
thought to be mediated through a combination of direct effects on cancer cells and the 
host’s immune system, resulting in improve recognition and subsequent destruction of 
cancer cells through non-specific and specific cell-mediated mechanisms[4]. More recent 
examples of cancer vaccines include Gardisil, a preventative vaccine approved by the FDA 
for cervical cancer in 2006, and Sipuleucel-T (Provenge®), approved by the FDA in 2010 
for the treatment of prostate cancer. Sipuleucel-T is a cell-based therapeutic vaccine that 
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utilizes patient’s own white blood cells, particularly dendritic cells, to fight off cancer. 
After a brief stimulation ex vivo with a fusion protein consisting of the antigen prostatic 
acid phosphatase (PAP) and the granulocyte-macrophage colony stimulating factor (GM-
CSF), the resulting active blood product is reinfused into the patient (Fig. 3). In a double-
blind randomized phase III clinical trial, Sipuleucel-T showed a four-month overall 
survival benefit to patients with castration-resistant prostate cancer[5]. For this reason, 
Sipuleucel-T was the first human cancer treatment vaccine to be approved in the United 
States.  
 
 In addition to cancer vaccines, a new type of immunotherapy known as oncolytic 
virus therapy gained FDA approval in October 2015. The genetically engineered virus, 
called talimogene laherparepvec, or T-VEC, was altered to reduce its ability to cause herpes 
and instead, infect and preferentially kill cancer cells (Fig. 4). In a randomized phase III 
clinical trial, T-VEC shrank tumours in people with advanced melanoma and extended 
patient survival by a median of 4.4 months[6]. While newer cancer vaccines, oncolytic 
viruses, and other novel approaches such as the chimeric antigen receptor (CAR) T-cell 
therapy display promising potential, most of the success stories up-to-date have been 
demonstrated by monoclonal antibodies (mAbs). Since the approval of Rituximab in 1997, 
more than a dozen mAbs have been approved for cancer treatment (Fig. 5). Notable 
examples include the recently renowned immune checkpoint blockers, anti-CTLA-4[7, 8] 
and anti-PD-1[9-11], which significantly extend the survival and cause rapid tumor 
regression in patients with melanoma[12, 13] and other cancers. The recent approval of 
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daratumumab[14] and elotuzumab[15], the first antibody treatments for myeloma, further 












Figure 2. Three phases of Immunoediting. 
 










Figure 3. Mechanism of action of Sipuleucel‑T. 
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 Existing monoclonal antibody therapeutics on the market can be largely divided 
into five categories based on their mechanisms of action[16, 17]. The first category 
includes those that make cancer cells more susceptible to immune attacks. These mAbs 
achieve this by either improving the recognition of cancerous cells or preventing the 
immune system from shutting down via endogenous inhibitory pathways. Rituximab, for 
instance, binds to CD20 on B cells, rendering certain types of lymphomas more visible to 
the immune system. The second category of mAbs refers to those that block growth signals 
for the tumor. Cetuximab, a monoclonal antibody approved to treat colon cancer and head 
and neck cancers, attaches to the epidermal growth factor receptor on cancer cells thereby 
slowing or stopping their growth. The third category consists of antiangiogenic mAbs. As 
cancer cells rely heavily on oxygen and nutrients in the blood, angiogenesis has been found 
to be an important therapeutic target in controlling tumor growth and expansion. The 
monoclonal antibody bevacizumab targets the vascular endothelial growth factor (VEGF) 
and restrict the growth of new blood vessels around tumors. Monoclonal antibodies that 
deliver radiation and chemotherapy to cancer cells make up the fourth and fifth categories, 
respectively. Examples include ibritumomab, approved for non-Hodgkin's lymphoma, and 
trastuzumab emtansine, which is approved to treat HER2-positive breast cancer.  
 
 In terms of design, mAbs can be naked, conjugated, or bispecific. Naked mAbs are 
antibodies that work by themselves and are the most common form of mAbs. Conjugated 
antibodies are mAbs that are linked to either a chemotherapeutic or a radioactive ligand. 
Bispecific antibodies, on the other hand, are made up parts of two different antibodies, 
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allowing them to recognize and bind two antigens even if the antigens are on different cells. 
For example, blinatumomab, which is used to treat certain subtypes of acute lymphocytic 
leukemia, can bind to both CD19 and CD3 on cancer and immune cells simultaneously and 
by doing so, enhance immune recognition and destruction of the cancer cells.  
 
 Lastly, upon binding by tumor-specific mAbs, cancer cells can die via direct 
signaling-induced death or immune-mediated mechanisms such as antibody-dependent 
cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CMC). Figures 6 


















Figure 6. Monoclonal antibody-based cancer therapeutic strategies. 
 
(A) Immunoglobulin G (IgG) molecules that bind to target cancer cells mediating antibody-
dependent cellular cytotoxicity (ADCC), inducing complement-mediated cytotoxicity (CMC) or 
result in the direct signaling-induced death of cancer cells (for example, herceptin and rituximab). 
(B) IgG mAbs inhibiting angiogenesis (for example, bevacizumab). (C), IgG mAbs blocking 
inhibitory signals, thereby resulting in a stronger antitumour T cell response (for example, 
ipilimumab and nivolumab). (D) Radioimmunoconjugates. (E) Antibody–drug conjugates (for 
example, brentuximab vedotin and trastuzumab emtansine) delivering highly potent toxic drugs to 
the cancer cells. (F) Bispecific antibodies (for example, blinatumomab). (G) Tumor-specific T-cells 
with chimeric antigen receptors (CAR) are generated by a gene therapy approach in which DNA 
for a mAb variable region fused to signaling peptides is transferred to T cells. CD3, T cell surface 
glycoprotein CD3 ε-chain; CTLA4, cytotoxic T lymphocyte-associated antigen 4; PD1, programmed 
cell death protein 1; PDL1, PD1 ligand; VEGF, vascular endothelial growth factor; VEGFR, VEGF 
receptor. 







Figure 7. Mechanisms of action of monoclonal antibodies that target cancer cells. 
 
 













Antibodies and Antibody-Drug Conjugates (ADCs) 
 As mentioned above, one way of enhancing the therapeutic potential of mAbs is by 
conjugating them to small-molecule drugs, such as the case of Brentuximab vedotin and 
T-DM1 (trastuzumab emtansine). These antibody-drug conjugates (ADCs) combine the 
efficacy of potent chemotherapeutics and the specificity from mAbs to target and destroy 
cancer cells without harming patient’s healthy cells. However, the need to site-specifically 
incorporate a small-molecule drug through a linker to an antibody and produce a 
homogeneous mixture at a large-scale remains a major challenge in this field[19-21].  
 
 Moreover, the choice of linker is also an important consideration when designing 
ADCs. In general, linkers can be categorized into two groups: those that are cleavable and 
those that are not (Fig. 8 and 9). The decision to use a cleavable linker or a non-cleavable 
one is made largely based on the desired pharmacokinetic profile including the distribution 
and delivery of the small-molecule drug. Cleavable linkers usually contain chemical motifs 
such as disulfides[22, 23], hydrazones[24, 25], or peptides[26-28]. These linkages are 
either enzyme-sensitive or pH-sensitive within the target tissue or target cell to ensure a 
controlled release of potent, often cytotoxic, chemotherapeutics. After the cytotoxic 
payload is released, however, it can escape from the target cell and attack the neighboring 
cells or tissues in a process called ‘bystander killing’[29]. Non-cleavable linkages such as 
-S-C- bonds can protect the host from such bystander killing since the small-molecule 
moiety stays with the antibody. In the context of clinical safety, this means non-cleavable 
linkers can lead to even lower side effects and wider therapeutic window. In my thesis 
research, we employed expressed protein ligation (EPL)[30] to connect the small molecule 
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ZM-241,385 (ZM), a selective antagonist of the A2AR, via a non-cleavable linker to the 
immunoglobulin Fc region (Fc) as a therapeutic strategy for enhancing the immune 




























Immune Checkpoint Blockers 
 Tumor antigens are readily recognized by the immune system as foreign based on 
their unique and mutational profiles. However, not all interactions between the immune 
cells and cancer lead to destruction of the cancer cell. This phenomenon is known as 
immune tolerance, where the cancer cell is recognized and determined as ‘self’. Immune 
tolerance is influenced by multiple factors, including the regulatory immune cells, anti-
inflammatory cytokines, and the ‘immune checkpoint’ pathways. One dominant immune 
checkpoint pathway present in the tumor microenvironment is the programmed cell death 
protein 1 (PD1) and PD1 ligand 1 (PDL1) receptor–ligand pair (Fig. 10). The natural 
function of the PD1 pathway in maintaining immune homeostasis is exploited in many 
cancers. In fact, mAbs that block this pathway have demonstrated powerful clinical 
efficacy against unresectable metastatic melanoma and treatment-refractory metastatic 
non-small-cell lung cancer and renal cell carcinoma. Durable objective (partial or 
complete) responses range from 31 – 44% in patients with advanced melanoma[11, 13, 31-
33], to 19 – 20% in patients with non-small-cell lung cancer[34-36], and 22 – 25% in 
patients with renal cell carcinoma[37, 38]. 
 
 In addition to the PD1 pathway, there are many other receptor – ligand interactions 
that could be targeted as immune checkpoint pathways. For example, ipilimumab, a mAb 
that binds to the prototypical immune checkpoint cytotoxic T lymphocyte associated 
antigen 4 (CTLA4), was approved in 2011 by the FDA for advanced melanoma[7, 39]. 
Unlike the PD1 pathway, however, the CTLA4 immune checkpoint predominantly 
functions early in the immune response, during T cell priming and activation (Fig. 11).  
19 
 
Interestingly, a recent study in patients with advanced melanoma, a combination of 
anti‑CTLA4 (ipilimumab) with anti‑PD1 (nivolumab) mAbs showed a robust objective 
response rate in 53% of patients, all with tumor reduction of 80% or more[12]. Such study 
raises the potential for other combinational treatment regimens using immune checkpoint 
blockers and further highlights the need for continual identification and understanding of 
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Figure 11. Distinct mechanisms of PD-1 and CTLA4 in immunosuppression. 
 
 
(A) PD-1 controls the effector phase of the immunity by inducing unresponsiveness through 
attenuating antigen-specific signals. Only CD8+ T cells are included here. MHC, major 
histocompatibility complex. (B) CTLA-4 controls, in particular, the function of activated CD4+ T cells 
that express Foxp3. CTLA-4 dominantly captures CD80 and CD86 on antigen-presenting cell 
(APC) and down-modulates the costimulatory activity of CD28 on effector T cells. TGF-β1, an 
important cytokine produced by Foxp3+ T cells, supports the growth and differentiation of Foxp3+ 
T cells and suppresses diverse immune responses. 
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Immunology of Adenosine and the Adenosine Receptors 
 Adenosine is a purine nucleoside known to affect the immune system[40]. The 
accumulation of adenosine is anti-inflammatory and leads to the inhibition of T cell 
activation and expansion[41, 42]. This normally acts as a feedback system to protect the 
host tissue from damage by auto-immune responses or over-inflammation[43]. However, 
high levels of adenosine are also found within the tumor microenvironment due to 
hypoxia[44] and inflammation which promote the generation and inhibit the degradation 
of adenosine[45]. This provides tumors a way to dampen the response and evade 
destruction by the immune system (Fig. 12). Fortunately, at the same time, it also provides 
a potential route for pharmacologic intervention and a platform for new cancer 
immunotherapeutic development. 
 
 The adenosine receptors (ARs) are G protein-coupled receptors (GPCRs) that can 
be found in four different subtypes, designated A1, A2A, A2B, and A3. They are expressed 
throughout the heart, the brain, and the immune system including lymphocytes, 
macrophages, and NK cells. Of the four subtypes of adenosine receptors, A2AR is the 
predominantly expressed subtype in most immune cells (Fig. 13)[46]. In particular, A2AR 
have been found to down-regulate activated immune cells upon activation by an agonist[47, 
48]. In the context of cancer, this down-regulation translates to the inhibition of NK cell 
cytotoxicity and tumor-specific CD4 and CD8 cell activity[49, 50]. Surprisingly, even after 
the removal of A2AR agonists, the effector function of T cells remains impaired [48, 51], 
suggesting that the adenosine-rich environment in tumors may induce T cells that are 
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anergic to the tumor cells. Consistent with this change, A2AR stimulation induces 
immunoregulatory molecules such as CTLA-4 and PD-1 on T cells [52-54].  
 
 Besides the T cells, antigen-presenting cells (APCs) are also affected by adenosine. 
Studies have found A2AR agonists to suppress IL-12 and induce IL-10 production from 
APCs, discouraging cellular immune response[55, 56]. Furthermore, T cell activation in 
the presence of A2AR stimulation markedly increases CD4+ FoxP3+ cells[53, 57-59]. 
FoxP3, a key transcriptional factor for the immunosuppressive activity of Treg cells, was 
also found to be inducible upon A2AR stimulation[48]. Overall, A2AR antagonists, like the 
checkpoint blocker anti-PD-1, presents promising potential in preventing tolerance and 
anergy during the immune response against cancer (Fig. 14). Furthermore, A2AR 
antagonists could also be combined with other current and developing immunotherapies to 













Figure 12. Adenosine pathway in the tumor microenvironment. 
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Figure 13. Summary of the Distribution of Adenosine Receptors. 
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Figure 14. Pro-Cancer Activities of Extracellular Adenosine and Therapeutic 
Targets for Cancer Immunotherapy. 
 
 
Tissue hypoxia in tumors increases extracellular adenosine production through induction of CD39 
and CD73. Produced adenosine transmits immunosuppressive signals through adenosine 
receptors on various immune cells. Potential target molecules in include the adenosine receptors 
(A2AR and A2BR) and adenosine producing enzymes (CD39 and CD73). Oxygen supplementation 
can also decrease pro-cancer effects of the adenosine pathway. 
 











Generation of the Protein-Small Molecule Conjugate Fc-ZM 
Introduction 
Agonist and Antagonist of the Adenosine 2A Receptor 
 As discussed in Chapter 1, adenosine receptors have distinct distributions in the 
human body, and therefore control different functions. The A2A receptor, in particular, is 
important in mediating vasodilation[62], supporting the synthesis of new blood vessels[63] 
and protecting tissues from excessive inflammatory damage. Numerous pharmacologic 
candidates that target the A2AR have been developed for this reason. Notably, a selective 
A2A adenosine receptor agonist, Regadenoson, was approved by the FDA in 2008 for 
coronary vasodilation during cardiac nuclear stress tests. Many other agonists and 
antagonists are also currently undergoing clinical trials, validating the therapeutic potential 
of A2AR modulation. 
 
 Early attempts in the development of A2AR agonists found that the adenosine 
scaffold and its stereochemistry was critically important and must be conserved as a 
structural basis for agonist design. Therefore, most of the modifications were centered 
around the N6 of the 2-position of the purine and at the 5’-position of the ribose, with the 
goal to achieve better metabolic stability compared to the natural ligand, adenosine[64]. 
One of the molecules that culminated from these studies was CGS21680, a moderately 
A2AR selective agonist that displays binding affinities of 27 and 19 nM at the human and 
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rat A2AR, respectively (Fig. 15)[65, 66]. The A2AR binding of CGS21680 is 10-fold 
selective against A1R and has a similar potency on A3R (hA3 Ki = 67 nM), whereas it is 
highly selective against A2BR (hA2B Ki > 10 000 nM). However, like most adenosine-based 
ligands, CGS21680 exhibited poor oral bioavailability and short in vivo half-lives due to 
the presence of three hydrogen bond donors in the ribose which are critical for A2AR 
activation but are subject to extensive metabolism. Later research focused on improving 
the pharmacokinetic and A2AR selectivity profiles, which led to the successful invention of 
Regadenoson (Fig. 16). Interesting, Regadenoson has a 2 to 3 min biological half-life, as 
compared with adenosine's 10-second half-life. 
 
 Unlike the agonists, antagonists of the A2AR lack the ribose moiety and are usually 
made up of mono-, bi-, or tricyclic structures that mimic the adenine part of adenosine. 
They are classified as xanthines and non-xanthines. Examples of xanthines include caffeine 
and theophylline, which are natural non-selective AR antagonists. However, due to the 
poor water solubility and instability associated with xanthine derivatives, scientists began 
to search for new classes of A2AR antagonists in the late 1980s. As part of this search. the 
Zeneca group developed ZM-241,385 (Fig. 17)[67], a potent bicyclic non-xanthine 
antagonist (hA2A Ki = 0.8 nM) that is selective over the A1 and A3 receptors (hA1 Ki = 255 
nM, hA3 Ki > 10 000 nM) although also potent at the A2B AR (hA2B Ki = 50 nM) (Fig. 
18)[64]. In animal models, ZM has been shown to protect against beta amyloid 
neurotoxicity[68] and enhance L-DOPA derived dopamine release[69], and therefore was 
thought to be useful in the treatment of Alzheimer's disease and Parkinson's disease. 
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 Due to its potency and selectivity against the A2AR, we selected ZM as our 
candidate for the development of a novel immune checkpoint blocker. However, since ZM 
was originally developed for the treatment of Parkinson’s disease, there are a number of 
design considerations when repurposing it for immune enhancement. First and foremost, 
ZM was found to have a short pharmacokinetic half-life (less than 20 min in cats), whether 
administered orally or intravenously[70, 71], with no detectable levels present in the 
plasma 4 h after oral administration. In a study in anaesthetized dogs, an apparent loss of 
cardiovascular activity was observed after 2 h following an intravenous administration[72]. 
Secondly, in addition to expression in T lymphocytes, A2AR is also abundant in the brain 
and heart and thus high doses of ZM could result in neuro- or cardio-toxicity. We 
hypothesized that by attaching ZM to Fc, the resulting conjugate Fc-ZM could overcome 













Figure 17. Examples of adenosine A2A receptor antagonists. 
 


















Structure of Adenosine 2A Receptor and Binding of ZM-241,385 
 The adenosine receptors display the topology typical of GPCRs, with a central core 
consisting of seven transmembrane helices. At the amino acid level, the human A2A AR 
shares 49% sequence identity with human A1 AR, 58% with human A2B AR, and only 41% 
with the human A3 AR. Considering residues responsible for the ligand binding, however, 
the average sequence identity is 71%, indicating high degrees of conservation. In 2008, 
Jaakola et al. published the crystal structure of A2AR bound to ZM[73], and three years 
after, crystal structures of the A2AR bound to the agonists adenosine and 5'-N-
ethylcarboxamidoadenosine (NECA) were resolved[74]. Binding interactions of the A2AR 
with adenosine and ZM are illustrated in Figure 19. 
 
 As shown in Figure 20, the bicyclic triazolotriazine core of ZM is anchored by an 
aromatic stacking interaction with Phe168 and an aliphatic hydrophobic interaction with 
Ile274. Analysis of the shape of the binding pocket shows that it consists of a deep, planar, 
and narrow cavity[75]. Importantly, the phenolic hydroxyl group extending from the 
ethylamine chain forms a hydrogen bond with an ordered water molecule towards the 
solvent-exposed extracellular regions, while the phenyl ring forms hydrophobic 
interactions with Leu267 and Met270. Additionally, affinity to the A2AR was found to be 
unaffected when the phenylmethylene group is replaced by a cycloalkyl substituent[76], 
demonstrating a high degree of substituent flexibility in this area of the pharmacophore. 
For this reason, we chose the phenolic hydroxyl group as our point of attachment for the 
linker and the Fc protein. 
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Figure 19. Crystal Structure: Binding Pocket of Adenosine 2A Receptor. 
 
 
Overlap between the crystal structures solved with the agonist adenosine (yellow) and the 
antagonist ZM241385 (cyan). 
 









































Fc-Fusion Protein Therapeutics 
 Many of the biological and pharmacological properties of mAbs can be found in 
the immunoglobulin (Ig) constant region Fc domain. In fact, fusing Fc to other molecules 
have shown to dramatically increase the in vivo half-life, as seen in the case of the anti-
TNFα drug etanercept. This increase in half-life could be attributed to the slower renal 
clearance for macromolecules as well as recycling through the neonatal Fc receptor 
(FcRn)[77]. Indeed, in a review published by Levin et al., the authors reported a correlation 
between the in vivo half-lives of Fc-fusion drugs and therapeutic mAbs and their FcRn-
binding affinities (Fig. 21)[78]. In addition to the improved serum half-life, Fc fusion has 
also shown to enhance other properties such as stability and solubility. In the case of ZM, 
the attachment of Fc could further prevent it from liver metabolism, additionally 
contributing to prolonged therapeutic activity. Moreover, Fc-ZM may show enhanced 
localization to tumors and other inflamed tissue sites given the presence of Fc receptors on 
antigen presenting cells and the enhanced permeability and retention effect[79] in the 
surrounding vasculature. From an industrial perspective, the use of Fc can be advantageous 
for the manufacturing process, as the production and purification processes offer the 
opportunity to be simpler than mAbs and ADCs. 
 
 One common but important concern in the development of biologics is 
immunogenicity. For Fc-fusion therapeutics, additional consideration is needed due to the 
immunological consequences resulting from interactions between the Fc domain and its 
canonical receptors. In addition to binding the FcRn, the Fc of IgG molecules also interacts 
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with various FcγRs and has critical biological effector functions like activating 
complement, mediating phagocytosis, and antibody-dependent cell-mediated cytotoxicity. 
Whether an interaction leads to an activating or inhibitory immune response depends on 
the specific motif associated with the receptor[80]. The activating receptors contain or 
associate with the immunoreceptor tyrosine-based activation motif (ITAM) as part of their 
intracytoplasmic structure, whereas the only inhibitory receptor in both humans and mice, 
namely FcγRIIB, has an immunoreceptor tyrosine-based inhibition motif (ITIM). 
Furthermore, the IgG receptors also vary in their binding affinities to each IgG subclass (1, 
2, 3, and 4 in humans and 1, 2a, 2b, and 3 in mice) as shown in Figures 22 and 23. In our 
studies, we chose the Fc domain of mouse IgG3 for its low affinity to essentially all IgG 
receptors except FcRn. 
 
 Lastly, it is worth noting that furthering the understanding of the biology in Fc–FcR 
interactions would be helpful in assessing the risks associated with this class of therapies 
as more engineered protein therapeutics that incorporate the Fc moiety enters the drug 
development pipeline. More importantly, this knowledge can be used to improve the 
pharmacologic profiles of the drugs based on the clinical needs of individual diseases. For 
example, Fc from the IgA molecule can be used to target conditions involving the mucosa 






Figure 21. Properties of the Fc fragment of fusion-protein drugs compared with 
therapeutic mAbs and human IgG1. 
 
 
(A) Comparison of the half-life of Fc-fusion drugs (blue circles), therapeutic mAbs (red squares), 
and IgG1 (green triangle). (B) FcRn-binding affinities (nM) of Fc-fusion drugs (blue circles) and 
therapeutic mAbs (red squares). (C) Correlation between half-life and FcRn-binding affinities of Fc-
fusion drugs and therapeutic mAbs. (D) Binding affinities for therapeutic targets (CD80, CD86) and 
FcRn are depicted for three generations of CTLA-4–Fc-fusion drugs. The active moiety CTLA-4 
(orange cylinder) and Fc (green cylinder) were both engineered. Abatacept is the parent molecule 
and affinities are depicted as blue bars. The CTLA-4 domain was engineered in the second-
generation belatacept, resulting in increased binding affinity for CD80 and CD86 but with no effect 
on affinity for FcRn (red bars). In the third-generation XPro9523, both the CTLA-4 and Fc domains 
were engineered, resulting in increased affinity for CD80, CD86, and FcRn (green bars). 
 
Levin D, Golding B, Strome SE, Sauna ZE. Fc fusion as a platform technology: potential for 






Figure 22. Human IgG receptors. 
 
 
Schematic representation of human IgG receptors at the cell membrane (gray bar) and their 
association or not to the FcRγ-chain dimer (black). Green boxes represent ITAMs; and the white 
box, the ITIM. Binding of a human IgG subclass is indicated in bold (high affinity), plain (low affinity), 
or between parentheses (very low affinity). - indicates no binding. 
 
Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease 












Figure 23. Mouse IgG receptors. 
 
 
Schematic representation of mouse IgG receptors at the cell membrane (gray bar) and their 
association or not to the FcRγ-chain dimer (black). Green boxes represent ITAMs; and the white 
box, the ITIM. Binding of a mouse IgG subclass is indicated in bold (high affinity), plain (low affinity), 
or between parentheses (very low affinity). - indicates no binding. 
 
Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease 











Expressed Protein Ligation (EPL) 
 Expressed protein ligation (EPL) is a technique that allows for the incorporation of 
an N-terminal cysteine-containing peptide to the C-terminus of a recombinant protein with 
a C-terminal thioester group in a precise and efficient manner[30]. For this reason, EPL is 
commonly used for flourophore labeling[84], isotope incorporation for NMR 
spectrometry[85], and generation of semi-synthetic proteins containing specific post-
translational modifications of interest[86]. Here, we have employed EPL to install ZM onto 
the C-terminus of the truncated mouse IgG3 Fc domain. 
 
 EPL involves the action of inteins (internal protein sequences), which are protein 
domains that act analogously to the introns of RNA molecules[87]. Specifically, the inteins 
are engineered in EPL so that the self-splicing reaction is interrupted in the first step during 
the intramolecular N,S-acyl shift (Fig. 24). In this project, we designed the expression 
construct so that the mouse IgG3 Fc is secreted with a intein fused with a chitin binding 
domain (CBD) at the C-terminus. The CBD domain is used as an affinity tag for chitin 
bead binding. The junction between Fc and the intein is induced by the intein to form a C-
terminal thioester, which is in equilibrium state with the native amide bond. This transient 
thioester can then react with sodium mercaptoethanesulfonate (MESNA), and then C-ZM 
(modified ZM with a linker containing six ethylene glycol units and a terminal Cysteine) 





Figure 24. Expressed protein ligation. 
 
 
The amino-terminal peptide of the target protein is expressed in cells as a fusion protein with an 
intein that has been modified to eliminate the branched ligation. Thiols (R = benzyl, phenyl, alkyl, 
CH2CH2SO3Na) are used to cleave the intein and generate a reactive carboxy-terminal thioester. 
This construct is then reacted with a peptide generated by solid phase peptide synthesis that 
contains an amino-terminal cysteine and an unnatural amino acid(s) in the position of interest. 
Reaction between the two constructs results in thiotransesterification, followed by S to N acyl shift 
to regenerate a peptide. 
 
Minnihan EC, Yokoyama K, Stubbe J. Unnatural amino acids: better than the real things?. F1000 














Materials and Methods 
Synthesis of A-ZM.  
tert-Butyl (E)-3-(4-(cyanomethyl)phenyl)acrylate (Intermediate A).  
 A mixture of 4-hydroxybenzyl cyanide (1, 5.00 g, 37.6 mmol) and powdered 
K2CO3 (12.7 g, 76.6 mmol) were dissolved in N,N-dimethylformamide (40 mL). Then, 
tert-butyl bromoacetate (7.4 mL, 50 mmol) was dissolved in N,N-dimethylformamide (10 
mL) and added dropwise to the reaction at room temperature. The mixture was vigorously 
stirred at 40 °C for 16 h resulting in the formation of a white precipitate. The reaction was 
allowed to cool and then poured into water (150 mL). The organic products were extracted 
with dichloromethane (3 x 25 mL) and the combined organic extracts were washed with 
water (3 x 100 mL), brine (50 mL), dried with anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude yellow oil was purified by column chromatography 
(SiO2, 10-25% EtOAc/hexanes) to yield the desired product as a slightly yellow, viscous 
oil (7.6 g, 81%). 1H NMR (500 MHz, CDCl3): δ 1.41 (s, 9H), 3.58 (s, 2H), 4.44 (s, 2H), 
6.80 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 8.8 Hz, 2H). 13C NMR (125 MHz, CDCl3): δ 22.22, 
27.59, 65.19, 81.94, 114.71, 117.85, 122.53, 128.75 157.19, 167.34. ESI-LRMS: [M+H]+ 
= m/z 248.2.  
 
3-(Furan-2-yl)-1H-1,2,4-triazol-5-amine (3).  
 2-Furonitrile (2, 5.0 g, 0.05 mmol) was first dissolved in 3 mL of absolute ethanol 
and cooled to 0 °C in an ice bath. Dry hydrogen chloride gas was then bubbled into the 
mixture for 3 min after which diethyl ether was added to precipitate a solid intermediate. 
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The isolated solid was then dissolved in pyridine (30 mL) and to it was added 
aminoguanidine nitrate (7.4 g, 0.05 mmol). The mixture was heated to reflux for 4 h after 
which it was cooled to RT, filtered, and the filtrate concentrated in vacuo. The resulting 
crude oil was placed on ice and treated with an aqueous solution 8M HNO3 (40 mL). The 
newly formed precipitate was isolated by filtration and washed with cold H2O (10 mL) and 
ethanol (5 mL). The nitrate salt was suspended in near boiling H2O (30 mL) with stirring 
and to it was added sodium carbonate in small portions (~1.30 g). Heating was continued 
until solids were completely dissolved, then the solution was allowed to cool to RT and 
subsequently placed on ice. The resulting precipitate was isolated by filtration, washed with 
H2O (3 x 5 mL), and dried to provide the title compound as a colorless prism (3, 2.37 g, 
29%). 1H NMR (500 MHz, DMSO-d6): δ 6.06 (s, 2H), 6.54 (s, 1H), 6.68 (s, 1H), 7.68 (s, 
1H), 12.08 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ 107.53, 111.30, 142.68, 147.68, 
152.15, 157.05. ESI-LRMS: [M+H]+ = m/z 151.2. 
 
2-(Furan-2-yl)-5-(methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (4). 
 Compound 3 (2.18 g, 14.5 mmol) and dimethyl N-cyanodithioiminocarbonate (2.33 
g, 16.0 mmol) were placed in a round-bottomed flask fitted with a condenser under argon. 
The neat mixture was heated to 170 °C for 1 h with stirring being initiated after compounds 
began to melt. . The reaction was then cooled to RT and the resulting solid was dry loaded 
and chromatographed on silica (0-50% EtOAc/DCM) to yield the desired compound as a 
colorless solid (4, 1.71 g, 48%). 1H NMR (500 MHz, DMSO-d6): δ 2.51 (s, 3H), 6.71 (dd, 
J = 3.4 Hz, 1.8 Hz, 1H), 7.16 (dd, J = 3.4 Hz, 0.7 Hz, 1H), 7.92 (dd, J = 1.7 Hz, 0.8 Hz, 
47 
 
1H), 8.86 (br, 2H). 13C NMR (125 MHz, DMSO-d6): δ 13.60, 112.12, 112.57, 145.25, 




 A solution of 3-chloroperoxybenzoic acid (6.88 g, 39.7 mmol) in dichloromethane 
(60 mL) was added to a stirred, ice-cooled suspension of compound 4 (1.5 g, 6.1 mmol) in 
dichloromethane (60 mL). The resulting suspension was allowed to warm to ambient 
temperature and stirring was continued for 16 h. The solvent was evaporated and the 
resulting solid triturated in ethanol (30 mL). The suspension was then cooled on ice and 
the precipitate isolated by filtration to provide the desired material as a white, crystalline 
solid (1.4 g, 83%). 1H NMR (500 MHz, DMSO-d6): δ 3.37 (s, 3H), 6.76 (dd, J = 3.3 Hz, 
1.7 Hz, 1H), 7.27 (d, J = 3.5 Hz, 1H), 7.99 (m, 1H), 9.65 (br, 2H). 13C NMR (125 MHz, 
DMSO-d6): δ 38.89, 112.34, 113.42, 144.97, 145.79, 152.19, 156.84, 157.32, 165.30. ESI-
LRMS: [M+H]+ = m/z 281.0. 
 
2-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)ethyl)phenyl)acetic acid (A-ZM).  
 Intermediate A (3.80 g, 15.4 mmol) was dissolved in 100 mL of 2-propanol in a 
Parr shaker together with 25 mL of 1N HCl and 1 g of the 10% Pd/C catalyst. The reaction 
mixture was hydrogenated at 50 psi and shaken for 6 h at room temperature. The reaction 
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was then filtered through a bed of Celite and the filter cake was washed with isopropanol 
(100 mL). The combined filtrate and wash were concentrated in vacuo and then partitioned 
between saturated aqueous sodium bicarbonate (50 mL) and diethyl ether (50 mL). The 
organic layer was isolated and the aqueous layer was further extracted with diethyl ether 
(30 mL). The combined organic extracts were dried with anhydrous sodium sulfate, 
filtered, and concentrated in vacuo to yield compound 5 as a colorless oil that was used in 
the next step without further purification. Compound 5 was then diluted in acetonitrile (5 
mL) and slowly added to a solution of Intermediate B, also dissolved in acetonitrile (5 mL). 
The reaction mixture was stirred for 16 h at room temperature after which the solvent was 
removed in vacuo and the reaction chromatographed on silica (5% MeOH/DCM) to 
provide a viscous yellow oil. The oil was taken up in ethyl acetate and recrystallized to 
yield the penultimate ester, tert-butyl 2-(4-(2-((7amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-yl)amino)ethyl)phenyl)acetate, as a white solid (yield: 0.6 g, 76%). 1H 
NMR (500 MHz, DMSO-d6): δ 1.41 (s, 9H), 2.78 (m, 2H), 3.45 (m, 2H), 4.59 (s, 2H), 6.67 
(s, 1H), 6.82 (d, J = 8.3 Hz, 2H), 7.05 (d, J = 3.1 Hz, 1H), 7.16 (d, J = 8.2 Hz, 2H), 7.46 
(m, 1H), 7.86 (s, 1H), 8.28 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ 27.69, 33.87, 
42.36, 65.00, 81.29, 111.61, 111.90, 114.32, 129.58, 132.11, 144.61, 146.19, 150.01, 
155.80, 156.06, 159.19, 161.08, 167.96. ESI-LRMS: [M+H]+ = m/z 452.2. 
 
The tert-butyl ester (0.40 g, 0.89 mmol) was dissolved in a 3:1:1 mixture of 
tetrahydrofuran/methanol/water (20 mL) and to it was added lithium hydroxide (0.17 g, 7.1 
mmol). The reaction was stirred at room temperature for 1 h after which it was complete 
as evidenced by TLC. Then, the mixture was acidified to pH 2 with 1N HCl and the 
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resulting precipitate was isolated by filtration and washed with water to provide the title 
compound as a white solid (0.28 g, 79%). 1H NMR (500 MHz, DMSO-d6): δ 2.78 (t, J = 
7.5 Hz, 2H), 3.44 (m, 2H), 4.62 (s, 2H), 6.67 (dd, J = 3.3 Hz, 1.7 Hz, 1H), 6.84 (d, J = 8.6, 
2H), 7.05 (dd, J = 3.5 Hz, 0.8 Hz, 1H), 7.17 (m, 2H), 7.50 (m, 1H), 7.86 (s, 1H), 8.30 (m, 
2H) (Fig. 26). 13C NMR (125 MHz, DMSO-d6): δ 33.82, 42.44, 64.48, 112.01, 112.38, 
114.30, 129.59, 131.94, 144.91, 145.14, 145.53, 149.94, 156.16, 158.53, 160.99, 170.26 
(Fig. 27). ESI-HRMS: calcd. for C18H18N7O4: [M+H]+ = m/z 396.1420, found: [M+H]+ = 






































































































Chemical Formula: C18H17N7O4 
Monoisotopic mass: 395.1342 g/mol 
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Synthesis of C-ZM.  
 tert-Butyl (14-amino-5-oxo-1,1,1-triphenyl-9,12-dioxa-2-thia-6-azatetra decan-4-
yl) carbamate (0.20 g, 0.33 mmol), synthesized as previously described[88], was dissolved 
in anhydrous tetrahydrofuran (3 mL) and added to PAL resin (MidWest Bio-Tech) (0.10 
g, 0.09 mmol) suspended in anhydrous THF (2 mL). Glacial acetic acid (0.10 mL) was 
added to this mixture and the reaction was allowed to stir at room temperature for 1 h. 
Then, NaBH(OAc)3 (0.16 g, 0.77 mmol) was added and stirring was continued overnight. 
The resin was then washed with methanol (5 x 5 mL), N,N-dimethylformamide (5 x 5 mL) 
and dichloromethane (5 x 5 mL) in a Bio-Rad Poly-Prep Chromatography Column. The 
subsequent coupling reactions with Fmoc-8-amino-3,6-dioxaoctanoic acid (139 mg, 0.35 
mmol each reaction) and A-ZM (17.8 mg, 0.045 mmol prepared as previously described) 
were based on standard solid phase peptide synthesis methodology. Coupling was carried 
out at room temperature for 3 h with 5% diisopropylethylamine (1.8 mL) and O-
(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU, 133 mg, 
0.35 mmol). Fluorenylmethoxycarbonyl deprotection was carried out at room temperature 
for 1 h with 20% piperidine (3 mL). The solvent used for both reactions was N-methyl-2-
pyrrolidone (NMP). The crude product was cleaved from the PAL resin with 4 mL of a 
95% TFA (trifluoroacetic acid), 2.5% ddH2O and 2.5% triisopropylsilane solution at room 
temperature for 1 hour, dried under vacuum, resuspended in 7 mL of ddH2O containing 
0.05% TFA and then filtered through a 0.2 μm filter to remove all insoluble particles. The 
filtrate was further purified by reverse-phase high performance liquid chromatography 
(HPLC), Varian Dynamax Microsorb 100-5 C18 column (250 x 21.4 mm), gradient: 5% 
to 60% acetonitrile/ddH2O over 50 min; 60%-100% acetonitrile/H2O, 5 min, 100% 
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acetonitrile, 10 min; 100%-5%, 10 minutes, the flow rate was 10 mL per minute. The final 
purified product, C-ZM, was lyophilized and isolated as a fine brownish powder (16 mg, 
13%). Compound characterization was done via analytical HPLC and electrospray 









































Synthesis of Fc-ZM.  
 The Fc domain of mouse IgG3 gene (aa 104-330) was expressed and isolated as 
previously described[88]. Briefly, Sf9 insect cells were grown in serum-free media (Sf-900 
III, Invitrogen) in suspension culture at 27°C. Fc-intein-CBD recombinant protein was 
expressed and secreted by Sf9 insect cells to the supernatant, which was collected by 
centrifugation at 1,500 rpm for 10 minutes and filtering through a 0.2μm filter to remove 
the cell pellet and debris. The Fc-intein-CBD fusion protien was then purified by passing 
the supernatant over a bed of chitin beads (NEB, 2 mL bed volume per liter culture) by 
gravity flow. The beads were washed with 50 mL of phosphate buffered saline (PBS) 5 
times before subjected to ligation with C-ZM. To initiate the ligation with C-ZM, 1-2 
column volumes of 400 mM sodium 2-mercaptoethanesulfonate in PBS (pH = 7.4) 
containing more than 100 molar equivalents of C-ZM was added to the column. The 
column was purged with argon and the reaction was carried out at room temperature over 
72 hours. The ligated product was eluted from the column with 1 column volume of PBS 
5 times, and dialyzed against 4 liters of PBS using a 10 kDa molecular weight cutoff 
(MWCO) dialysis cassette (Slidealyzer). Each buffer exchange lasted at least 6 hours, with 
a total of six buffer exchanges. The final Fc-ZM was further concentrated to 0.5-1 mg/mL 







Liquid Chromatography Mass Spectrometry (LC-MS) analysis of Fc-ZM.  
 LC-MS was performed on a LXQ system (Thermo Scientific) with a Poroshell 
300SB-C8 column (5 um, 75 x 1.0 mm). Fc-ZM was first digested with PNGase F (New 
England Biolabs) according to the protocol provided by the manufacturer. The digested 
sample was then treated with 50 mM DTT and heated at 55 °C for 20 minutes before 
subjecting to LC-MS analysis. The LC was performed at 60 °C eluting with a linear 
gradient of 20-40% acetonitrile:water containing 0.1% formic acid within 10 minutes at a 














Results and Discussions 
Synthesis of Fc-ZM. 
 In designing Fc-ZM, we considered the key role that derivatizing the ZM small 
molecule would play that would preserve its potent antagonist function.  We thus pursued 
the chemical synthesis of A-ZM (Fig. 31), a form of ZM in which the phenol would be 
derivatized with a carbolic acid that could be convenient for connecting a synthetic linker. 
Prior X-ray crystallographic studies of ZM in complex with the A2AR revealed that the 
phenol was relatively solvent exposed[73].  We thus predicted that A-ZM would retain the 
pharmacodynamic properties of the parent compound ZM.  The synthesis of A-ZM began 
with commercially available 4-hydroxybenzonitrile 1 which was alkylated with tbutyl 
bromoacetate to generate intermediate A. At the same time, the sulfone building block, 
intermediate B, was prepared according to previously published procedures[89-91].  
Briefly, the commercially available 2-furonitrile starting material 2 was cyclized with 
aminoguanidine to generate amniotriazole 3. Condensation of 3 with N-
cyanodithioiminocarbonate provided heterocyclic thioether 4 which was subsequently 
oxidized with mCPBA to yield sulfone intermediate B. With the two building blocks A and 
B in hand, A-ZM was generated by first hydrogenating intermediate A to afford 
phenethylamine 5. Nucleophilic displacement of the sulfone with the resulting primary 
amine and subsequent base-catalyzed removal of the t-butyl group provided the desired 
compound in seven overall steps.  Separately, we prepared an ethylene-oxy linker 
terminating in a Cys resiude by solid phase synthesis for use in expressed protein ligation. 
The size of this linker was projected to be of sufficient length, about 100 angstroms in 
extended conformation, to allow for dual engagement of the ZM with A2AR and the Fc 
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domain with Fc receptors, present on different cell types.  Given previous success with Fc-
CGS, this consisted of the structure shown for C-ZM (Fig. 32).  
 
 With C-ZM in hand, it was ligated to the Fc protein via expressed protein ligation. 
In order to produce Fc in its glycosylated, disulfide-linked form, we expressed an Fc-intein-
chitin binding domain (CBD) construct containing the mouse IgG3 Fc domain (Scheme 1) 
in Sf9 insect cells via the baculovirus expression system as previously described. The 
secreted Fc-intein-CBD was isolated, purified with chitin resin, and treated with 2-
mercaptoethanesulfonate sodium (MESNA) to form the free Fc thioester. The Fc thioester 
was then reacted with C-ZM or cysteine to make Fc-ZM and Fc, respectively. We chose 
EPL to ensure chemoselective ligation at the C-terminus of the Fc protein and for its 
technical simplicity to perform with high yields in comparison to other methods. SDS-
PAGE revealed Fc and Fc-ZM with more than 90% purity based on Coomassie staining 


















Figure 32. Synthetic scheme of C-ZM. 
 
 
Synthesis of C-ZM. A-ZM was attached to an ethylene-oxy linker terminating in a Cys residue, 
which was generated via solid-phase peptide synthesis (SPPS) techniques.  SPPS conditions 
include: (a) coupling: Fmoc-NH-(PEG)-COOH, HBTU, 5% DIPEA, NMP, RT, 3 h, and (b) 













Liquid chromatography mass spectrometry (LC-MS) spectrum confirming the expected mass of Fc-
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Ex vivo and in vivo characterization of Fc-ZM 
Introduction 
 In Chapter 2, we demonstrated the successful synthesis and purification of Fc-ZM. 
Here, we characterize the functionality, efficacy, and safety of Fc-ZM in various ex vivo 
and in vivo immune models. 
 
Suppression of the Adenosine Pathway in Murine Models 
 One of the sources of extracellular adenosine is from ATP metabolism by the 
surface nucleotidases, CD39 and CD73. CD39 catalyzes hydrolysis of ATP/ADP to AMP, 
and CD73 converts AMP to adenosine. As mentioned in Chapter 1, inflammation within 
the tumor environment induces focal hypoxia in the surrounding tissue. Hypoxia, in turn, 
increases the mRNA levels and enzymatic activities of CD39 and CD73[92, 93], and 
reduces the rate of adenosine removal by adenosine kinases[94, 95]. Interestingly, CD73 
expression has been reported in mouse tumor cell lines[96-98] and tumor cells from 
patients with various cancers[99-106]. The expression of CD73 was also found to correlate 
with poor prognosis of breast, ovarian, prostate, brain cancers, and leukemia. Knockdown 
of CD73 in tumor cells led to reduced growth in vivo and increased susceptibility to 
antitumor immune cells[107, 108]. Similarly, anti-CD73 antibody therapy also reduced 




 In addition to targeting the production of adenosine, others have focused on 
blocking the pathway at the receptor level. Preclinical studies using A2AR antagonists and 
knock-out mouse models have illustrated the significance of adenosine in tumor survival 
by demonstrating tumor regression after the inactivation of adenosine receptors (Fig. 
35)[61, 110]. In 2006, Ohta et al. showed that A2AR-deficient mice could spontaneously 
regress the inoculated tumor, whereas no wild-type mice exhibited similar tumor 
regression[110]. Likewise, A2AR antagonists were also beneficial in tumor-bearing wild-
type animals. Importantly, depletion of T cells and NK cells impaired the retardation of 
tumor growth by A2AR antagonists, suggesting the effector functions of these immune cells 
are susceptible to A2AR modulation[111]. 
 
 Interesting, a recent report published by Cekic and Linden found that although 
A2AR-deficient T cells can effectively elicit antitumor activities in the adenosine-rich tumor 
microenvironment, they may disappear prematurely before complete tumor regression and 
hence result in tumor regrowth[112]. In a separate study by Koszałka et al., the authors 
actually found the activation of any adenosine receptor to significantly inhibit B16F10 
melanoma growth but only at its early stages[113]. Therefore, further studies to understand 
better dosing and timing of A2AR antagonists is important in improving current treatment 







Figure 35. Overview of experimental strategies to test the hypothetical 
mechanism of tumor protection via the adenosine pathway. 
 
 
It is assumed that adenosine and A2AR, which inhibit overactive immune cells to protect normal 
tissues, may protect malignant tissues from antitumor T cells. Genetic targeting of A2AR may de-
inhibit CD8+ T cells and thereby facilitate their antitumor effector functions. A similar outcome could 
be accomplished by using A2AR antagonists. 
 
Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. 















Expected Pharmacologic Properties of Fc-ZM 
 As discusses earlier, Fc-conjugated therapeutics and ADCs have been found 
to exhibit elimination half-lives in the range of days to weeks[78]. For the clinically 
approved ADCs in their first-in-human Phase 1 studies: trastuzumab emtansine decayed 
with a half-life of 3.10 days, brentuximab vedotin decayed with a half-life of 4.43 days, 
and a previously approved ADC gemtuzumab ozogamicin decayed with a 3.02 days (Fig. 
36)[114]. Consistent with these observations, our previous study using 
immunohistochemistry revealed Fc-CGS at the target tissue site even weeks after the final 
dose[88]. Therefore, in the ex vivo and in vivo experiments described later in this Chapter, 
we sought to test whether Fc-ZM has similar half-life in the range of days. In addition to 
pharmacokinetic improvements, we also anticipated a pharmacodynamics effect from 
covalently linking Fc and ZM. Specifically, Fc-ZM may display high functional affinity 
against the A2AR due to engagements at both A2AR and FcRs on the same cell or 
neighboring cells. This enhanced functional affinity, or avidity, is based on the 
accumulated strength of multiple individual receptor binding events, where any binding 
interaction increases the likelihood of another to occur (Fig. 37)[115]. The implication of 
such enhanced affinity could mean the use of lower dose to achieve the same efficacy, 








Figure 36. Comparative Pharmacokinetic Parameters of ADCs in Humans. 
 
 
MTD, Maximum Tolerated Dose; DAR, Drug-to-Antibody Ratio; Cmax, maximum (or peak) serum 
concentration; AUC, Area Under the Curve; CL, Clearance; t1/2, Half-life; Vss, Apparent Volume 
of Distribution at Steady State. 
 
Deslandes A. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human 














Figure 37. Multivalency in Ligand Design. 
 
 
(A) A monovalent ligand binds a monovalent receptor with a dissociation constant Kd affinity. (B) A 
bivalent ligand binds a receptor of the same valency with a dissociation constant of Kd,2 (avidity). 
(C) The bivalent receptor binds its ligand with only one receptor-ligand interaction, with a 
dissociation constant of Kd,1. The enhancement (β) is the ratio of affinity to avidity. 
 
Krishnamurthy, V. M., Estroff, L. A. and Whitesides, G. M. (2006) Multivalency in Ligand Design, in 
Fragment-based Approaches in Drug Discovery (eds W. Jahnke and D. A. Erlanson), Wiley-VCH 










Materials and Methods 
Intracellar cAMP (cyclic AMP) measurements via enzyme-linked immunosorbent 
assay.  
 Spleens from wild type (C57BL/6) mice were harvested and crushed on a cell 
strainer (BD Bioscience). The red blood cells were then removed using ACK lysis buffer. 
The isolated splenocytes were seeded in 96-well plates with AE7 medium (45% RPMI 
1640, 45% EHAA Clicks, 10% fetal bovine serum, 1% antibiotics, 1% L-Glutamine, 0.1% 
Gentamycin, 0.05% 2-Mercaptoethanol) and activated by 2ug/ml of soluble anti-CD3 and 
anti-CD28 for 48 hours, then rested in fresh medium without anti-CD3 or anti-CD28 for 
24 hours before drug treatments. To determine the effects of CGS, ZM, A-ZM, C-ZM, Fc, 
and Fc-ZM on A2AR function, the amount of total cAMP produced in wild type (C57BL/6) 
splenocytes was assayed with the cAMP Biotrak EIA system (GE Healthcare Life Science) 
according to manufacturer’s instructions. 
 
Surface Plasmon Resonance (SPR) Measurements.  
 SPR measurements were performed on a Biacore T200 instrument (GE 
Healthcare). FcRn and FcgRI were immobilized in different channels on a CM5 sensor 
chip (GE Healthcare) using amine coupling kit provided by the manufacturer. The sensor 
chip surface was activated with NHS and EDC followed by flowing of receptors until 2000 
resonance units (RU) were obtained. A blank reference cell was use as a reference. Fc and 
drug conjugated Fc (Fc-ZM) were flown over the cell as analytes. HBS-P+ buffer (10 mM 
HEPES, 150 mM NaCl, 0.05% surfactant P20, pH 7.4 or 6.4) were used as sample buffer 
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and running buffer. Association of analytes Fc and Fc-ZM were measured for three minutes 
with a flow rate of 20 µL/min and allowed to dissociate for another three minutes. The 
surface regeneration was achieved by 3M MgCl2 at a flow rate of 20 µL/min for 60 s. The 
analytes were injected in a series of two-fold diluted concentration of the highest 
concentration used (2 µM, 1 µM, 500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM etc 
and blanks). Multiple individual experiments were carried out and a typical curve is 
presented in the figures. All sensorgrams were reference channel and blank subtracted for 
analyses. Kinetics data were obtained by global fitting of the binding data to a 1:1 steady 
state affinity of Langmuir binding model using BIAcore T200 evaluation software (GE 
healthcare).   
 
Mice.  
 Mice above six-weeks of age were used for all the experiments in this study. All 
mouse procedures were approved by the Johns Hopkins University Institutional Animal 
Care and Use Committee. C57BL/6 mice were obtained from the Jackson Laboratory. 
A2AR knock-out mice were bred and housed in pathogen-free conditions on the Johns 
Hopkins School of Medicine East Baltimore campus. Mice deficient of the γ-chain subunit 






Ex vivo T cell response via Interferon γ ELISA.  
 Splenocytes from wild type (C57BL/6) mice, A2AR knock-out mice, and mice 
deficient of the γ-chain subunit of FcγR1, FcγRIII, and FcεRI (Model 583, Taconic) were 
isolated and cultured in round-bottom 96-well plates with AE7 medium (45% RPMI 1640, 
45% EHAA Clicks, 10% fetal bovine serum, 1% antibiotics, 1% L-Glutamine, 0.1% 
Gentamycin, 0.05% 2-Mercaptoethanol) over 48 hours, in the presence of 0.5 µg/ml of 
anti-CD3 and various drug treatments. Supernatants were harvested and the level of 
interferon γ was determined via ELISA (Mouse IFN gamma ELISA Ready-SET-Go!®, 
Affymetrix eBioscience). 
 
In vivo CD8 acute response to Vaccinia virus infection.  
 Wild type C57BL/6 (WTB6) mice were infected with Vaccinia virus expressing 
ovalbumin on day 1 via retro-orbital injections at 1 million plaque-forming unit (PFU) per 
mouse. Throughout days 2 to 6, various treatments were given via intraperitoneal 
injections, including vehicle (20% DMSO in PBS), CGS (5.0 µmol/kg, b.i.d.), CGS (5.0 
µmol/kg, b.i.d.) and ZM (8.9 µmol/kg, b.i.d.), CGS (5.0 µmol/kg, b.i.d.) and Fc (100 
nmol/kg, on days 2 and 4), CGS (5.0 µmol/kg, b.i.d.) and Fc-ZM (100 nmol/kg, on days 2 
and 4). Importantly, Fc and Fc-ZM was given one hour before CGS injections. On day 7, 





Statistical analysis.  
 All graphs were created using GraphPad Prism software, and statistical analysis 
was performed with GraphPad Prism. Comparisons between three or more independent 
groups were assessed by one-way ANOVA with a Tukey’s multiple-comparisons test. A P 
value less than 0.05 was considered statistically significant. 
 
In vivo cardiovascular toxicity study with CGS and Fc-CGS.  
 Wild type (C57BL/6) mice were anesthetized with 3% isoflurane and maintained 
under 2% isoflurane anesthesia throughout EKG acquisition. Anesthetized mice were 
placed in a supine position on a temperature controlled heating pad. Body temperature was 
monitored with rectal probe and maintained at 37–38°C. EKG probes were inserted 
subcutaneously and EKG signal (Standard lead II) was obtained using a PowerLab data 
acquisition system (ML866) and Animal Bio Amp (ML136; AD Instruments, Colorado 
Springs, CO, USA). Vehicle (PBS), 5 μmol/kg of CGS, or 50 nmol/kg of Fc-CGS was 
administered via intraperitoneal injections. 5 minutes of EKG signal were recorded prior 
to each injection, followed by 20 minutes of recording after the injection. LabChart Pro 7.2 







Results and Discussion 
Binding to the A2AR. 
 To explore the potential of Fc-ZM to bind and antagonize the A2AR, we treated WT 
mouse splenocytes with Fc-ZM and control compounds for 1 hour and measured the 
subsequent production of cyclic AMP (cAMP), a known second messenger in response to 
A2AR activation. The treatments were either done alone (Fig. 38A) or in combination with 
the A2AR agonist, CGS-21680 (Fig. 38B), to assess receptor antagonism. Moreover, the 
mouse splenocytes were pre-activated with 2 µg/ml of anti-CD3 and anti-CD28 to ensure 
maximal A2AR expression on the cell surface. As expected with A2AR activation, CGS 
treatment led to a dose-dependent increase in intracellular cAMP production. Treatments 
with ZM, A-ZM, C-ZM, or Fc demonstrated no changes in cAMP levels. When treated in 
combination with CGS, Fc-ZM and its ZM-containing precursors inhibited the production 
of cAMP in a dose-dependent manner. Notably, Fc-alone does not affect cAMP production 
induced by CGS, indicating the antagonism by Fc-ZM is due to a functional ZM moiety 










Binding to Fc Receptors. 
 Next we examined the ability and affinity of Fc-ZM to bind the Fc receptors. Mouse 
IgG3 is known to bind at low and high affinities to two Fc receptor isotypes: FcγRI and 
FcRn. FcγRI is typically found on dendritic cells where receptor binding leads to cell 
activation via the immunoreceptor tyrosine-based activation motif (ITAM). On the other 
hand, FcRn expression is found on most myeloid and lymphoid cell types except T cells, 
NK cells, and eosinophils. Functionally, FcRn is responsible for uptake, transport, and 
recycling of antibodies. Binding to FcRn occurs at the CH2-CH3 hinge region independent 
of Fc glycosylation[116, 117]. Unlike other Fc receptors, FcRn preferentially binds Fc at 
acidic pH[118], such as in endocytic vacuoles. Given the tumor microenvironment is 
highly acidic[119] due to glycolytic metabolism, hypoxia, and lack of blood perfusion, this 
characteristic of FcRn presents a potential mechanism by which Fc-conjugates can be 
recycled and concentrated locally within solid tumors. Therefore, we investigated the 
potential of Fc-ZM to bind both FcγRI the FcRn at pH 7.4 and pH 6.4 via surface plasmon 
resonance (SPR). In order to measure the affinities at low pH, we immobilized FcγRI and 
FcRn through amine coupling to the chips and injected Fc and Fc-ZM as analytes. As 
shown in Figure 39, both Fc and Fc-ZM were able to bind FcγRI and FcRn at pH 6.4, with 
the affinity to FcRn being approximately one order of magnitude higher than FcγRI. When 
the pH is increased from 6.4 to 7.4, affinity to FcγRI also increased by about 2-fold, 








Ex vivo T-cell Response. 
 We hypothesized that the covalent linkage between Fc and ZM through a short 
polyethylene glycol linker would enhance the immune response further than either moiety 
alone. To test this, we harvested and treated wild-type C57BL/6 mice splenocytes with Fc-
ZM and controls, in the presence of 0.5 µg/ml of anti-CD3 without or without CGS 
inhibition for 48 hours, and measured the level of interferon γ (IFNγ) accumulated in the 
supernatant. As expected, A2AR activation by CGS decreased the amount of IFNγ produced 
by the splenocytes whereas ZM had no effect on their IFNγ production (Fig. 41A). 
Interestingly, treatment with Fc alone resulted in increased level of IFNγ in the supernatant, 
presumably through the activation of immune cells via FcRs engagements. The addition of 
ZM with Fc did not further stimulate the cells except when the two molecules are 
covalently linked, as in the case of Fc-ZM. In fact, cells that were treated with Fc-ZM were 
robust producers of IFNγ, leading to extracellular levels that were 6-fold higher than that 
of the untreated cells. This increase caused by Fc-ZM suggests potential strengthening of 
cell-cell interactions between lymphocytes and antigen-presenting cells. In addition, the 
increase was observable even in the presence of a high concentration of CGS (9-fold molar 
excess, Fig. 41B), further confirming that the ZM remained active its ability to bind and 
inhibit the A2AR. 
 
 Furthermore, testing the same treatments in mice splenocytes lacking the A2AR 
(Fig. 42A and 42B) or the FcγRs (Fig. 43A and 43B) did not yield similar results, 
suggesting that the observed phenomenon is specific to the A2AR and the FcγRs. Overall, 
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the observation that Fc-ZM can increase IFNγ production from wild-type splenocytes 
significantly more than either drug alone demonstrates the benefits of a covalent linkage 
and is consistent with our hypothesis that a short linker of approximately 100 Å could 
enhance the immune response by facilitating cell-cell interactions between lymphocytes 


























In vivo Response to Vaccinia infection. 
 To examine whether the reversal of CGS effects by Fc-ZM observed ex vivo can be 
translated in vivo, we looked at its effects on the acute response to Vaccinia virus infection. 
In this model, we infected wild type C57BL/6 mice with Vaccinia virus expressing 
ovalbumin and treated them with various drug combinations over the five days post-
infection. Spleens were harvested on the sixth day post-infection and the number of 
splenocytes was quantified by counting (Fig. 44). In comparison to vehicle treatment, CGS 
treatment decreased the number of splenocytes by approximately three-fold. This 
inhibition was reversed by ZM when given twice daily to match the dosing schedule of 
CGS. When ZM was given once daily, the reversal was incomplete, suggesting that ZM is 
largely metabolized and/or cleared from the system by the time the second dose of CGS is 
administered (at least 4 hours after the first dose). By contrast, Fc-ZM, but not Fc, was able 
to reverse the inhibitory effects of CGS when given only two intraperitoneal injections total 
(day 1 and day 3 post-infection).  
  
 Consistent with our hypothesis, this ability of Fc-ZM to match ZM in reversing the 
immuno-inhibitory effects of CGS, even at a significantly reduced dosing frequency, is 
indicative of a prolonged half-life resulting in extended periods of antagonism at the A2AR. 
It is also important to note that the dose of Fc-ZM was 50-fold less in molar amounts 
compared to that of CGS. Given that the small-molecule ZM only has a 33-fold higher 
affinity to the A2AR than CGS[64], this matched reversal suggests that Fc-ZM, as a bivalent 
molecule, has an enhanced apparent affinity to the A2AR, potentially by engaging with 
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multiple A2ARs or with A2ARs and FcRs on neighboring lymphocytes and antigen-





















In vivo Cardiotoxicity of Fc-small molecule conjugates. 
 Previously, we synthesized a similar Fc protein-small molecule conjugate, Fc-CGS, 
which demonstrated enhanced pharmacokinetics and pharmacodynamics when compared 
to its small molecule counterpart, CGS, in treating pneumonitis in mice. Since the heart 
was known to have high levels of A2AR expression, we hypothesized that the improved 
therapeutic profile of Fc-CGS would lead to reduced cardiovascular toxicity when 
compared to CGS. To test this, we administered PBS, CGS (5 μmol/kg), and Fc-CGS (50 
nmol/kg) into anesthetized wild-type mice and monitored their heart rate changes via an 
electrocardiogram (EKG) for 20 minutes (Fig. 45A). Approximately 5 minutes following 
the intraperitoneal injection, CGS induced a significant increase in heart rate, or 
tachycardia (Fig. 45B). On the contrary, neither PBS nor Fc-CGS induced tachycardia in 
mice. This observation is consistent with our hypothesis that conjugation with Fc can 
enhance the pharmacologic properties of small-molecules such as CGS and ZM, resulting 















 My thesis research has focused on the design, synthesis, and testing of a novel Fc 
protein-small molecule conjugate, Fc-ZM, for the purpose of immune enhancement. The 
design strategy allowed for a controlled, site-specific conjugation between the Fc domain 
protein and the modified A2AR antagonist, A-ZM. Binding studies in vitro demonstrated 
the ability of Fc-ZM to bind FcRn and FcγRI, and functionally inhibit the activation of 
A2AR in a manner similar to its small-molecule precursor, ZM. In both ex vivo and in vivo 
immune response models, Fc-ZM exhibited superior pharmacokinetics and 
pharmacodynamics in antagonizing the A2AR when compared to ZM. Overall, we have 
illustrated a reproducible method of synthesizing Fc-conjugated small molecules, and its 
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